Aqara Smart Lock U200 Lite Brings Smart Access Control to More European Households
17.6.2025 09:00:00 CEST | Business Wire | Press Release
Aqara, global leader and pioneer in IoT, unveils the new Smart Lock U200 Lite, offering effortless access control, enhanced security, and a modern keyless lifestyle to more European households, particularly those seeking budget-friendly solutions. Designed for DIY installation, the U200 Lite features a retrofit design compatible with most Euro mortise locks. It also supports Matter over Thread to ensure compatibility with a wide range of connected devices and seamless integration into users’ existing smart home setup.
Built upon the Thread protocol, which is purposely developed for IoT devices, the Smart Lock U200 Lite is Matter-certified and integrates with major platforms – including Alexa, Apple Home, Google Home, Home Assistant, and SmartThings – without the need for a proprietary hub1. As an integral part of a connected home, the U200 Lite can be integrated with a variety of smart devices, from video doorbells, surveillance cameras to smart sensors, enabling users to create a customized and enhanced smart security system.
The U200 Lite is compatible with Euro mortise locks with the Emergency Function2, and supports EU profile and select Scandi profile cylinders. Its hassle-free retrofit design offers homeowners and renters an instant update to their existing locks, without the need for complex installations, key changes, or door modification.
Multiple secure door entry options are offered by the U200 Lite. Family members can conveniently unlock it using mobile apps (Aqara Home and other Matter-enabled apps) or voice commands via Siri and Alexa. More intuitively, they can also unlock by simply tapping their iOS and Android phones on the provided NFC Sticker Card, which can be placed on the outside of the front door. Even when away, homeowners can remotely open the door for visitors using the mobile app. All remote functionalities, such as real-time alerts, device logs, and remote unlocking, are provided subscription-free.
With its built-in gyroscope, the U200 Lite provides acoustic reminders if the door is not properly closed, ensuring it is never left unsecured. Once closed, it automatically locks, and there is no need for an external door sensor —offering a more aesthetically pleasing and cost-effective solution3. Other popular features that the U200 Lite model retains from its predecessor, the U200, include:
- Quiet Mode reduces the noise level during unlocking and locking3.
- Pull Spring automatically retracts the door latch upon unlocking3.
- Turn to Lock/Unlock allows effortless manual locking/unlocking3.
Equipped with a 2,000 mAh rechargeable Li-ion battery, the U200 Lite offers a battery life of up to 6 months on a single charge4, eliminating the hassle of frequent battery swaps and promoting an eco-friendly lifestyle.
The Aqara Smart Lock U200 Lite is now available for purchase through Aqara’s official website, authorized retailers, and major e-commerce platforms such as Amazon (France, Germany, Italy, Netherlands, Poland, Spain, UK).
For more information on the new smart lock, please visit the Aqara website.
- A Matter controller with Thread Border Router functionality is required for connecting the Smart Lock U200 Lite to any third-party Matter-enabled system, locking/unlocking remotely via a mobile app, and locking/unlocking with voice commands.
- The Emergency Function enables the cylinder to be unlocked from the outside using a key, even if another key is already inserted on the inside.
- The Auto Lock, Quiet Mode, Pull Spring, and Turn to Lock/Unlock features are disabled by default and can be only activated in the Aqara Home app setting.
- The 6-month battery life is based on the assumption of 8 cycles of unlocking and locking per day.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617169337/en/
Contacts
For Media Inquiries:
media@aqara.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom